Author: oncologs.com

MUSC Hollings Cancer Center researchers have unlocked a discovery that could help to explain why cancer can recur in patients who have undergone chemotherapy or radiotherapy. Credit: Medical University of South Carolina. Photograph by Sarah Pack. MUSC Hollings Cancer Center researchers have unlocked a discovery

Within the family of cell membrane lipids known as phosphoinositides and the kinase enzymes that regulate them, phosphoinositide 3-kinases (PI3Ks) have been cast in a starring role as scientists study their involvement in cancer, diabetes and many cellular activities. Credit: Sanford Burnham Prebys Within the

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and is projected to become the second-leading cause of cancer-related death by 2030. Although progress has been made in improving outcomes, the five-year survival rate remains stubbornly low at just 13%.   Credit: MUSC

A team of cancer researchers, led by the University of Houston, has discovered a new subset of T cells that may improve the outcome for patients treated with T-cell therapies.   Credit: University of Houston A team of cancer researchers, led by the University of

Hepatocellular carcinoma (HCC) cases with small nodules are commonly treated with radiofrequency ablation (RFA), but the recurrence rate remains high. This study aimed to establish a blood signature for identifying HCC with metastatic traits pre-RFA. Credit: Hui Xie, Kun Chen, Junxiao Wang, Liping Jiang Background

A new paper in Trends in Pharmacological Sciences from researchers at generative artificial intelligence (AI)- and robotics-powered clinical stage drug discovery company Insilico Medicine (“Insilico”) and ETH Zurich reveals the broad potential of TNIK as a therapeutic target for some of the most pervasive aging-related

A recent study led by Dr. Zhaohua Jiang from the Shanghai Ninth People’s Hospital has brought advancements in the treatment of lymphedema in breast cancer survivors. Through a procedure known as vascularized lymph node transfer (VLNT), Jiang and his team successfully demonstrated the restoration of

This study is led by Dr. Xun Lan (Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China), Dr. Jiafu Ji, Dr. Zhaode Bu (Center of Gastrointestinal Cancer, Peking University Cancer Hospital & Institute, Beijing, China), Dr. Honghao Yu (Guangxi Key Laboratory of

Cancer poses significant challenges due to the development of resistance and the likelihood of relapse. Resistance may arise from permanent genetic changes in cancer cells or non-genetic alterations in cancer cell behavior induced by treatment. Standard of care in cancer treatments typically involves administering the

Osaka, Japan – A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models. This will be a world-first in-human